Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 23;10:1012. doi: 10.3389/fonc.2020.01012

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 La Manna, De Menna, Patel, Karkampouna, De Filippo, Klima, Kloen, Beimers, Thalmann, Pelger, Jacinto and Kruithof-de Julio.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dose-response curves of LAPC9 (A) and BM18 (B) PDX organoids to mTOR-targeting drugs rapalink-1 (red circles), rapamycin (blue triangles), and everolimus (black diamonds) after 48 h treatment. Normalized viability values of organoids are plotted against log₁₀ drug concentrations; N = 2–3. Viability assay of LAPC9 (C) and BM18 (D) PDX organoids after treatment for 48 h with other, non mTOR-targeting drugs. The grayed area in plots (A–D) corresponds to the expected distribution of the reference condition (untreated). Data were analyzed by one-way ANOVA, treated conditions were compared to vehicle (DMSO, EtOH for abiraterone treatment); N = 2–3. *p < 0.05; **, §§p < 0.01; ***p < 0.001; ****p < 0.0001.